EGFR and non-small cell lung carcinoma: With a view of providing evidence for clinical and reimbursement decision‐making, the aim of the study was to assess the cost‐effectiveness of osimertinib in postoperative patients with completely resected IB to IIIA, EGFR‐mutated NSCLC.